Patent Application Titled "Ofatumumab For Treating Pediatric Ms" Published Online (USPTO 20240343821).

A patent application titled "Ofatumumab For Treating Pediatric Ms" was published online, highlighting the high burden of pediatric multiple sclerosis (MS) on patients and their families. Current treatment options for pediatric MS are limited, leading to a significant unmet medical need. Ofatumumab, a monoclonal antibody targeting CD20, has shown promise in treating MS in adults and is now being explored for pediatric MS patients, offering potential benefits for this vulnerable population. The patent application outlines the potential use of ofatumumab in treating or preventing MS in pediatric patients with specific weight and age criteria, presenting a novel approach to addressing the challenges faced by this patient group. [Extracted from the article]